Intracoronary epinephrine versus adenosine in the management of refractory no-reflow phenomenon: a single-center retrospective cohort study

Ahmed Darwish, Abdel-Fattah Frere, Magdy Abdelsamie, Waleed El Awady, Mohammad Gouda

From the Department of Cardiology, Zagazig University, Zagazig, Egypt

BACKGROUND: The no-reflow phenomenon is associated with a considerable reduction in myocardial salvage in patients with ST elevation myocardial infarction (STEMI) treated by primary percutaneous intervention (PCI). There has been no head-to-head comparison of intracoronary epinephrine to adenosine in the management of no-reflow phenomenon.

OBJECTIVES: Evaluate the short- and long-term efficacy and safety of using intracoronary epinephrine versus adenosine for management of the catastrophic no-reflow phenomenon that may occur during primary PCI.

DESIGN: Retrospective cohort.

SETTING: Single center in Egypt.

PATIENTS AND METHODS: The study included STEMI patients who developed refractory no-reflow phenomenon during primary PCI after failure of conventional treatments and received either intracoronary epinephrine or adenosine.

MAIN OUTCOME MEASURES: No-reflow management measured through improvement of thrombolysis in myocardial infarction grade (TIMI flow), myocardial blush grade, TIMI frame count and major adverse cardiovascular events (MACE) at 1-year follow up.

SAMPLE SIZE: 156 patients with refractory no-reflow phenomenon during primary PCI.

RESULTS: Successful reperfusion was achieved in 74 of 81 (91.4%) of patients who received epinephrine and in 65 of 75 (86.7%) who received adenosine (P<.05). Fifty-six of 81 patients (69.1%) achieved TIMI III flow after epinephrine administration versus 39 of 75 patients (52.7%) in the adenosine group (P=.04). The incidence of heart failure after 1 year of follow up was lower in the epinephrine group compared to the adenosine group (6.3% vs. 19.2%, P<.017). MACE after 1 year of follow up was lower in patients who received epinephrine compared to those who received adenosine (11.3 % Vs. 26.7 %, P<.01).

CONCLUSION: During primary PCI, intracoronary epinephrine is as effective as adenosine in successful management of refractory no-reflow phenomenon with a more favorable long-term prognosis compared to adenosine.

LIMITATIONS: Retrospective design.

CONFLICT OF INTEREST: None.
Percutaneous coronary intervention (PCI) is the standard treatment for patients with ST-segment elevation myocardial infarction (STEMI) according to the latest European Society of Cardiology guidelines. No-reflow, which is not uncommon during primary PCI, is defined as impaired myocardial perfusion that is attributed to microvascular obstruction despite opening the occluded epicardial coronary artery. The frequency of no-reflow phenomenon is reported to be around 0.6–5% in elective cases, but it may be encountered in up to 50% of primary PCI cases. After primary PCI, the presence of the no-reflow phenomenon has a poor prognosis due to a significant reduction in the myocardial perfusion and larger myocardial necrosis that usually impairs left ventricular function and increases cardiovascular mortality. Pharmacotherapy for the management of no-reflow has always taken two main strategies: local vasodilator and antiplatelet therapy. Intracoronary adenosine has been approved by American guidelines in the management of the no-reflow phenomenon. On the other hand, although epinephrine is one of the main agents in resuscitating arrested patients, there is little published data on its effectiveness in coronary no-reflow. This study aimed to evaluate the short- and long-term efficacy and safety of using intracoronary epinephrine versus adenosine for management of the catastrophic no-reflow phenomenon that may occur during primary PCI.

PATIENTS AND METHODS
This single center, retrospective cohort study, was conducted in the catheterization lab in the cardiology department of Zagazig University Hospital, Zagazig, Egypt, from April 2019 to April 2021. Written consent was obtained from patients to review their medical records after explanation of the medical research and publication process. The study was conducted according to the guidelines of the declaration of Helsinki, and approved by the institutional review board of Zagazig University Hospital, Sharkia, Egypt (approval number: ZU-IRB #5316/24-3-2019).

The study included STEMI patients who developed refractory no-reflow during primary PCI. No-reflow was defined as a reduction in antegrade TIMI (thrombolysis in myocardial infarction) flow grade (TIMI 0 and TIMI 1) after stent deployment after ruling out spasm, dissection, and acute stent thrombosis. No-reflow was defined as refractory when it did not resolve with administration of any two of the following medications: nitrates, verapamil and glycoprotein IIb/IIIa inhibitors. We excluded patients with cardiogenic shock at time of admission, known allergy to epinephrine or adenosine, non-ST elevation acute coronary syndrome, patients with electrical instability which contraindicated use of either epinephrine or adenosine such as sinus bradycardia, heart block, junctional rhythm, frequent extrasystoles, non-sustained and sustained ventricular tachycardia (VT), chronic hemodialysis, pregnancy, contraindications to dual antiplatelet therapy, need for emergent coronary artery bypass surgery and patients diagnosed as having COVID-19 using the PCR test (9 patients).

Baseline demographic and clinical data were obtained from all patients and physical examination was done with special attention to evaluate the patients clinically for signs of heart failure depending mainly on the Killip classification. The Grace score also was calculated for risk stratification of all included patients. All patients were premedicated before transfer to the catheterization lab with 300 mg aspirin, 180 mg ticagrelor, 80 mg atorvastatin and unfractionated heparin (70–100 IU/kg IV bolus when glycoprotein IIb/IIIa inhibitor was not planned to be used and 50–70 IU/kg when GP IIb/IIIa inhibitor was planned). The epinephrine regimen consisted of one ampule (1 mg/1 mL) diluted in 10 cc saline then 1 cc of epinephrine diluted 10 fold by adding 1 cc to 10 cc saline for a dose of 100 μg for intracoronary injection over 5 minutes through an aspiration catheter or a pierced balloon inflated at the culprit lesion. This dose could be repeated up to 3 times if needed, reaching a maximum dose of 400 μg. The adenosine regimen consisted of one ampule (6 mg/2 mL) diluted in 10 cc saline then 1 cc of adenosine diluted 10 fold by adding 1 cc to 10 cc saline; 1 cc of the solution was then added to another 10 cc saline to reach final concentration of 60 μg for intracoronary injection through an aspiration catheter or a pierced balloon inflated at the culprit lesion. Another dose was repeated once if needed, reaching a maximum dose of 120 μg.

Calculation of TIMI flow grade, myocardial blush grade (MBG) and TIMI frame count was done before and after drug administration. Procedural success was defined as ≤20% stenosis and improvement of TIMI flow and MBG to grade 2 or 3. Immediately after the procedure, bedside screening echocardiography was done to assess regional wall motion abnormalities, end systolic volume, end diastolic volume, ejection fraction using the Simpson biplane method, pulmonary artery pressure, presence, and degree of mitral regurgitation and other complications of myocardial infarction. We recorded development of acute renal failure and in hospital major adverse cardiac events (MACE) including heart failure, stroke and death. Follow up was done by reviewing patient medical records. In our center, patients are routinely scheduled for follow-up visits weekly.
for the first month after discharge then an outpatient visit every three months. Echocardiography assessment is done routinely three months post-primary PCI, one year after the procedure and in cases having any new event.

At the one year follow-up visit, all patients were assessed for regional wall motion abnormalities, left ventricular systolic function, and MACE including heart failure, stroke, recurrent myocardial infarction, repeat revascularization, and death. Heart failure was defined as a new onset of symptoms and/or signs of heart failure plus echocardiographic evidence of systolic dysfunction with ejection fraction less than 40%.

Data were analyzed using IBM SPSS version 23.0 (Armonk, New York, United States: IBM Corp). Qualitative data are shown as number and percentage and quantitative data are shown as mean and standard deviation, or median and interquartile range. The epinephrine and adenosine groups were compared using the independent sample t-test or the Mann-Whitney U test as appropriate. The paired t-test was used to compare the angiographic and echocardiographic parameters before and after drug use in each group separately. A P value of <.05 was considered statistically significant.

RESULTS

Of 1356 consecutive patients who presented to our catheterization lab with STEMI and underwent primary PCI from April 2019 to April 2021, 172 (12.7%) patients developed the refractory no-reflow phenomenon. After excluding 16 patients, 156 patients with refractory no-reflow who received either intracoronary epinephrine or adenosine were included in the analysis (Figure 1). Eighty-one received epinephrine and 75 received adenosine. The epinephrine group were given a cumulative dose 100-400 μg of intracoronary epinephrine; the adenosine group were given 60-120 μg of intracoronary adenosine over 5 minutes through aspiration catheter or pierced balloon inflated at the culprit lesion. With the exception of age, there was no significant difference between the two groups in demographics and risk factors including hypertension, diabetes, dyslipidemia, and smoking (Table 1). For time from symptom onset to primary PCI, there was no statistically significant difference between the two groups (Table 2). Successful reperfusion was achieved in 91.4% (75/81) of patients who received epinephrine and 86.7% (65/75) in those who received adenosine for no-reflow management (P=.35). The number of patients who achieved TIMI III flow after drug administration was higher in the epinephrine group (Table 2, Figure 2). MBG as well was higher in the epinephrine group compared to adenosine group (P=.04).

Most of the arrhythmic events in the epinephrine group were sinus tachycardia, which was reported in 28.4% of cases (Table 3). However, supraventricular tachycardia and non-sustained VT occurred only in 3.7% and 6.2% of cases in the epinephrine group, respectively, and was spontaneously terminated. Sustained VT was encountered only in one case which was successfully managed by direct current cardioversion. Also, transient heart block occurred in 1.3% of patients who received adenosine. Regarding in-hospital cardiovascular events, heart failure was numerically lower but statistically non-significant in the epinephrine group compared to adenosine. Otherwise, no significant difference was noted in clinical outcomes in the hospital.

At 1-year follow-up, LV ejection fraction showed a statistically significant improvement compared to baseline (56.3 [8.7] vs. 48.9 [7.9]; P<.001) in the epinephrine group, and in the adenosine group (54.1 [11.5] vs 49.1 [7.8]; P<.001). The difference in ejection fraction between the groups at 1 year was not statistically significant (P=.0179). On the other hand, at the 1-year follow up, the incidence of HF among patients who received epinephrine was lower compared to those who received adenosine (6.3% vs. 19.2%, P<.017) (Figure 3). Overall, MACE at 1 year were lower in the epinephrine group.
Table 1. Demographic data and risk factors for the two groups (n=156).

|                        | Epinephrine (n= 81) | Adenosine (n= 75) | P value |
|------------------------|---------------------|--------------------|---------|
| Age (median and IQR)   | 62 (9)              | 54 (11)            | <.001*  |
| Gender                 |                     |                    |         |
| Female                 | 37 (54.3)           | 29 (38.7)          | .376    |
| Male                   | 44 (45.7)           | 46 (61.3)          |         |
| Hypertension           | 43 (53.1)           | 44 (58.7)          | .483    |
| Diabetes mellitus      | 56 (69.1)           | 49 (65.3)          | .613    |
| Smoking                | 34 (42.0)           | 42 (56.0)          | .080    |
| Dyslipidemia           | 46 (56.8)           | 45 (60.0)          | .685    |
| Peripheral artery disease | 2 (2.5)           | 5 (6.7)            | .206    |
| Family history of premature coronary artery disease | 9 (11.1) | 12 (15.0) | .371 |

Data are n (%) unless noted otherwise. *Mann-Whitney U test.

Table 2. Angiographic analysis of the two groups.

| Angiographic variables                         | Epinephrine (n=81) | Adenosine (n=75) | P       |
|------------------------------------------------|--------------------|-------------------|---------|
| Time to PCI (hours)                            | 10 (15)            | 10 (20)           | .329*   |
| Diseased vessels                               | 1.53 (0.7)         | 1.67 (0.7)        | .24     |
| Culprit vessel                                 |                    |                   |         |
| Left anterior descending                       | 48 (59.3)          | 37 (49.3)         | .214    |
| Left circumflex artery                         | 17 (21.0)          | 14 (18.7)         | .717    |
| Right coronary artery                          | 16 (19.8)          | 24 (32)           | .08     |
| Aspiration Use                                 | 21 (25.9)          | 20 (26.7)         | .92     |
| Reflow (TIMI grade ) before drug               | 0.27 (0.4)         | 0.41 (0.4)        | .06     |
| TIMI 0 after drug                              | 0 (0)              | 1 (1.4)           | .29     |
| TIMI 1 after drug                              | 7 (8.6)            | 9 (12.2)          | .47     |
| TIMI 2 after drug                              | 18 (22.2)          | 26 (35.1)         | .08     |
| TIMI 3 after drug                              | 56 (69.1)          | 39 (52.7)         | .04     |
| Myocardial blush grade after drug              | 3 (1)              | 2 (1)             | .04*    |
| TIMI frame count before drug use               | 59.07 (9.4)        | 58.49 (9.4)       | .69     |
| TIMI frame count after drug use                | 19.62 (6.2)        | 21.48 (6.8)       | .076    |
| Successful reperfusion (TIMI 2, 3)             |                    |                   |         |
| Yes                                            | 74 (91.4)          | 65 (86.7)         | .35     |
| No                                             | 7 (8.6)            | 10 (13.3)         |         |

Data are n (%) unless noted otherwise. *Median (IQR), Mann-Whitney U test. TIMI: Thrombolysis in myocardial infarction.
EPIEKRINE AND ADENOSINE

Figure 2. TIMI flow grade after epinephrine and adenosine administration (percent of total for each drug) (see Table 2 for statistical comparisons).

Table 3. Clinical outcomes in hospital and after 1 year.

|                         | Epinephrine (n= 81) | Adenosine (n= 75) | P value |
|-------------------------|---------------------|-------------------|---------|
| In-hospital cardiovascular outcome |                     |                   |         |
| Sinus tachycardia        | 23 (28.4)           | 0                 | <.001   |
| Supraventricular tachycardia | 3 (3.7)            | 0                 | .09     |
| Non-sustained ventricular tachycardia | 5 (6.2)         | 0                 | .03     |
| Sustained ventricular tachycardia | 1 (1.2)           | 0                 | .33     |
| Heart block              | 0                   | 1 (1.3)           | .29     |
| Heart failure            | 5 (6.2)             | 8 (10.7)          | .310    |
| Death                    | 1 (1.2)             | 0                 | .33     |
| Major adverse cardiovascular event | 6 (7.4)      | 8 (10.7)          | .477    |
| Acute renal failure      | 3 (3.7)             | 1 (1.3)           | .35     |
| 1-year cardiovascular outcome |                   |                   |         |
| Heart failure            | 5 (6.3)             | 14 (19.2)         | .02     |
| Recurrent myocardial infarction | 2 (2.5)         | 3 (4.1)           | .59     |
| Stroke                   | 1 (1.3)             | 2 (2.7)           | .51     |
| Death                    | 1 (1.2)             | 2 (2.7)           | .52     |
| Major adverse cardiovascular event | 9 (11.3)     | 20 (26.7)         | .01     |

Data are n (%).

rime group compared to the adenosine group (11.3% Vs. 26.7%, P<.01). This difference was attributed to the significant decrease in heart failure events, while differences in other events were statistically non-significant.

DISCUSSION

The development of the no-reflow phenomenon is indicative of a poor prognosis, and is usually associated with a significant reduction in myocardial salvage in patients with STEMI. In response to reduced myocardial perfusion, larger myocardial necrosis occurs, which subsequently impairs left ventricular function and increases mortality. On short-term follow up, the no-reflow phenomenon has been associated in different studies with prolonged hospitalization compared with patients without no-reflow. In a study conducted on 1140 patients, development of no-reflow during primary PCI was associated with larger infarct size, impaired left ventricular systolic function at 6 months and increased 1-year mortality risk. On long-term follow up, no-reflow was proven to be a strong predictor of 5-year mortality.

Classically, management of no-reflow depends on intracoronary vasodilator and antiplatelet drugs to target both vasospastic and thromboembolic mecha-
Patients who develop no-reflow usually presented with hypotension; intracoronary epinephrine administration may restore normal blood pressure in those patients by stimulation of alpha vasoconstrictor receptors. In addition, correction of hypotension improves coronary perfusion, which may be another potential mechanism in aborting no-reflow. Another potential explanation for the role of epinephrine in no-reflow is that it has potent beta-2 receptor agonist properties that mediate coronary vasodilatation.

Regarding the safety of epinephrine, sinus tachycardia was the most frequently encountered arrhythmia. Supraventricular tachycardia and VT developed in a minority of patients, which is consistent with the findings of Aksu et al who did not report any sustained VT after intracoronary epinephrine. This lack of sustained VT could be due to distal intracoronary injection of epinephrine rather than its injection through the guide catheter. This explanation is supported by the findings of Abu Arab et al who demonstrated that heart rate changes after guide catheter delivery of medications were greater than changes after local distal delivery through aspiration catheter or pierced balloon.

Adenosine was proven to be effective as well for management of no-reflow phenomenon. This may be explained by the studies showing that regional myocardial blood flow was significantly better in the adenosine-treated animals. The beneficial effect also extended beyond vasodilatation to preservation of vascular endothelium in the ischemic areas. On the other hand, a major limitation of adenosine is its short half-life. Recent studies revealed that a 2-hour intracoronary adenosine infusion is better than an adenosine bolus in aborting no-reflow. However, the main issue regarding adenosine infusion is that it may result in atrioventricular block. Accordingly, adenosine cannot be used in the setting of heart block, sinus bradycardia and junctional rhythm, which are not uncommon during STEMI and primary PCI.

Only a few studies that were conducted on epinephrine and adenosine for management of no-reflow were concerned with the long-term clinical follow up of the patient as most of the studies depended on angiographic assessment and in-hospital follow up. To our knowledge, this is the first head-to-head study comparing the long-term clinical outcome of epinephrine versus adenosine for no-reflow management. Regarding one year adverse cardiovascular events, the present study showed that MACE after 1-year of follow up was lower in epinephrine arm compared to adenosine. This result was supported by the findings of Navarese et al who reported a significantly lower 30-day MACE rate.
among patients treated with intracoronary epinephrine compared to conventional treatment with or without adenosine. Furthermore, the incidence of heart failure after 1-year follow up was lower in patients who received epinephrine compared to those who received adenosine. This result is in agreement with Aksu et al.\textsuperscript{16} who showed that left ventricular volumes had decreased in a statistically significant manner compared to baseline after using intracoronary epinephrine for no-reflow treatment. On the other hand, Navarese et al.\textsuperscript{17} reported a numerically lower but statistically non-significant number of heart failure events at 30 days of follow up in the epinephrine-treated group. This result may be explained by the difference in sample size as they conducted their analysis only on 14 patients receiving epinephrine while our study analyzed 81 patients receiving epinephrine for no-reflow, which gave enough power for our statistically significant results.

Limitations of our study are that the study design is observational and consequently may be subject to unknown confounders and biases. Therefore, we recommend performing large randomized double-blind clinical trials to compare the effect of epinephrine against adenosine in no-reflow management. Given that cardiac magnetic resonance imaging is the gold standard modality to assess microvascular obstruction, we recommend studying epinephrine effect on microcirculation using cardiac MRI post-primary PCI. In conclusion, intracoronary epinephrine administration improved immediate angiographic outcome and long-term LV systolic function in refractory no-reflow. Therefore, intracoronary epinephrine could be an effective bail out management for the refractory no-reflow phenomenon during primary PCI of STEMI patients, especially in cases of failure or contraindications to other conventional agents.
REFERENCES

1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Duca C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2017;39(2):119-77. doi: 10.1093/eurheartj/ehx393. European Heart Journal.

2. Adejji J, Muller O, Eckehout A. E. Handbook of Primary PCI: No-Reflow Management. In: Watson TJ, Ong PJJ, Tcheng JE, editors. Primary Angioplasty: A Practical Guide. Singapore: Springer Singapore; 2018. p. 223-35.

3. Yang L, Cong H, Lu Y, Chen X, Liu Y. Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. 2020;99(26):e20152. doi: 10.1016/j.jacc.2009.12.054. PubMed PMID: 20488311.

4. Gupta S, Gupta MM. No-reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian heart journal. 2016;68(0):539-51. Epub 2016/04/19. doi: 10.1016/j.ihj.2016.04.006. PubMed PMID: 27543480.

5. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23):e747-e81. Epub 2011/11/09. doi: 10.1161/CIR.0b013e31823ba622. PubMed PMID: 22064601.

6. Goto Y, Maeda T, Goto Y. Effects of pre-hospital epinephrine during out-of-hospital cardiac arrest with initial non-shockable rhythm: an observational cohort study. Crit Care. 2013;17(5):R188. Epub 2013/09/02. doi: 10.1186/cc12872. PubMed PMID: 24004456; PubMed Central PMCID: PMC3840562.

7. Muller O, Windescker S, Cuisset T, Fajadet J, Mason M, Zuffi A, et al. Management of two major complications in the cardiac catheterization laboratory: the no-reflow phenomenon and coronary perforations. EuroIntervention. 2008;4(2):181-3. Epub 2008/12/30. doi: 10.4244/eijv4i2a32. PubMed PMID: 19110779.

8. Gilchrist I. Killip class is still relevant. Crit Care Med. 2011 Mar;39(3):580-1.

9. Bradshaw PJ, Ko DT, Newman AM, Donovran LR, Tu JV. Validity of the GRACE (Global Registry of Acute Coronary Events) acute coronary syndrome prediction model for six month post-discharge death in an independent dataset. Heart. 2005 Jul;92(7):905-9.

10. Hassan AKM, Mohamed HSE, Mohamed AM, Ahmed TAN, Kishki Y. Predictors of no-reflow in patients undergoing primary percutaneous coronary intervention. Thrombosis aspiration was protective. The Egyptian heart journal. 2018;70(4):421-6. Epub 2018/08/12. doi: 10.1016/j. ejhj.2018.07.007. PubMed PMID: 30591766.

11. Roe MT, Ohman EM, Maas AC, Christensen RH, Mahaffey KW, Granger CB, et al. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol. 2001;37(1):9-18. Epub 2001/01/12. doi: 10.1016/s0735-1097(00)01101-3. PubMed PMID: 11153779.

12. Bedajou A, Benkhedda S, Sediki S, Allal K, Belhadi CE, Azaza A, et al. Intracoronary or intravenous abciximab after aspiration thrombectomy in patients with STEMI undergoing primary percutaneous coronary intervention. 2019;30(1):45-51. doi: 10.5830/CVJA-2018-063.

13. Bouleti C, Mewton N, Germain S. The no-reflow phenomenon: State of the art. Arch Cardiovasc Dis. 2015;108(12):661-74. Epub 2015/12/06. doi: 10.1016/j.acvd.2015.09.006. PubMed PMID: 26616729.

14. Nidrepoga P, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010;55(21):2383-9. Epub 2010/05/22. doi: 10.1016/j.jacc.2009.12.054. PubMed PMID: 20483311.

15. Skelding KA, Goldstein JA, Mehta L, Pica MC, O’Neill WW. Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv. 2002;57(3):305-9. Epub 2002/11/01. doi: 10.1002/cdc103. PubMed PMID: 12410503.

16. Aksu T, Guler TE, Colak A, Baysal E, Durukan M, Sen T, et al. Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective study. BMC cardiovascular disorders. 2015;15:10. doi: 10.1186/s12872-015-0004-6. PubMed PMID: 25885120.

17. Navarase E, Frediani L, Kandzari DE, Caiasso G, Cennrime AM, Cortese B, et al. Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory no-reflow during primary PCI: The RESTORE observational study. Catheter Cardiovasc Interv. 2021;97(4):602-11. Epub 2020/07/18. doi: 10.1002/ccd.29113. PubMed PMID: 32678493.

18. DiCarlo SE, Blair RW, Bishop VS, Stone HL. Role of beta-2-adrenergic receptors on coronary resistance during exercise. J Appl Physiol (1985). 1988;66(6):2287-93. Epub 1988/06/01. doi: 10.1152/jappl.1988.66.6.2287. PubMed PMID: 2902333.

19. Aksu T, Guler TE, Colak A, Baysal E, Durukan M, Sen T, et al. Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective study. BMC cardiovascular disorders. 2015;15:10. doi: 10.1186/s12872-015-0004-6. PubMed PMID: 25885120; PubMed Central PMCID: PMC4353473.

20. Abu Arab T, Rafik R, El Etiry A. Efficacy and Safety of Local Intracoronary Drug Delivery in Treatment of No-Reflow Phenomenon: A Pilot Study. J Interv Cardiol. 2016;29(5):496-504. Epub 2016/07/29. doi: 10.1111/jioc.12318. PubMed PMID: 27463533.

21. Marzilli M, Orsini E, Marraccini P, Testa RJC. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. 2000;101(18):2154-9.

22. Rezkalaa SH, Stankowski RV, Hanna J, Kliener RA. Management of No-Reflow Phenomenon in the Catheterization Laboratory. JACC: Cardiovascular Interventions. 2017;10(3):215-23. doi: https://doi.org/10.1016/j.jcin.2016.11.059.